Two different clinical-stage NLRP3 inhibitors, NT-0249 and NT-0796, have demonstrated that inhibiting NLRP3 reverses established diet-induced obesity in mice and provides metabolic benefits that extend beyond reversing obesity itself [76]. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.